Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
besifloxacin
- Development stage
- Approved
- Lead developer
- Bausch & Lomb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
Besifloxacin is a fourth-generation fluoroquinolone antibiotic developed for ophthalmic use, specifically as an eye drop suspension. It is indicated for the topical treatment of bacterial conjunctivitis (pinkeye), an infection of the membrane covering the outside of the eyeballs and inside of the eyelids. Besifloxacin acts by inhibiting two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are required for DNA replication, transcription, repair, and decatenation during cell division. This dual inhibition impairs bacterial proliferation and survival. The drug was FDA approved in 2009 and is supplied as a 0.6% ophthalmic suspension[1][2][3][4][5][6].
- Brand names
- Besivance
- Other names
- BESIFLOXACIN (MART.)BESIFLOXACINEbesifloxacinobesifloxacinum
02
Targets
GyrA (DNA gyrase subunit A)Topo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on besifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on besifloxacin.